Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics

Fig. 1

Flowchart of patient enrollment. HCC, hepatocellular carcinoma; PD-1 Programmed death 1. *For training and validation of the model, use about 2/3 to 4/5 of the sample for training, and the rest for validation [49]. The 2:1 ratio is a commonly used approach in machine learning and radiomics studies to balance the need for a comprehensive training dataset with the requirement for a substantial validation dataset

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us